%0 Journal Article
%@ 1369-7056
%A Ding, C
%A Jones, G
%D 2002
%F epprod:3523
%J IDrugs
%N 12
%P 1168-1172
%T Lumiracoxib (Novartis)
%U http://eprints.utas.edu.au/3523/
%V 5
%X Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.